Canada Common Drug Review (CDR) was established in 2003, it undertakes reviews of new drugs and provide formulary listing recommendations for all provinces ’ governments. PMPRB was established in 1988 to manage the national patent drugs’ prices. The determination of provinces’ patent drugs reimbursement payment standard s were on the consideration of CDR’s recommendations and PMPRB’s reference prices. Generic drugs’ price was controlled by province’s price negotiation and generic value price initiative. This study introduced the Canada CDR and price management system to provide reference for China reimbursement d rug list access and price negotiation.